查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2020216

荷爾蒙補充療法市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類，並預測至2026-2034年

Hormone Replacement Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 138 Pages | 商品交期: 請詢問到貨日

價格

荷爾蒙補充療法（HRT）市場的成長要素

受更年期症狀、生長激素缺乏症、甲狀腺機能低下症和男性性腺功能低下症患病率上升的推動，全球荷爾蒙補充療法（HRT）市場正經歷顯著成長。根據財富商業洞察（Fortune Business Insights）的數據顯示，2025年HRT市場規模為179.4億美元。預計到2026年，該市場規模將成長至190.4億美元，2034年進一步擴大至312.3億美元，預測期內複合年成長率（CAGR）為6.38%。

市場動態

荷爾蒙補充療法）不僅對治療女性更年期症狀（如潮熱、睡眠障礙、焦慮和骨質疏鬆）至關重要，而且對治療男性和兒童的荷爾蒙相關疾病也同樣重要。例如，生長激素缺乏症、甲狀腺機能低下症以及男性和兒童的男性性腺功能低下症，都在推動全球對HRT的採用。人們對現代治療方法的認知不斷提高，以及對雌激素療法、聯合治療、經皮和口服製劑的接受度不斷提高，都是推動市場擴張的關鍵因素。

新冠疫情期間，該市場曾經歷短暫下滑，主要原因是供不應求以及醫療機構營運中斷影響了診斷和治療。然而，隨著醫療服務的重新開放以及對這些療法的持續需求，市場成長已恢復至疫情前水準。

市場區隔

治療方法：

  • 雌激素及聯合治療：在人們對更年期症狀的認知不斷提高以及凝膠、貼劑和口服片劑等多種劑型的普及推動下，預計到2026年，雌激素及聯合療法將佔全球51.04%的市場佔有率，引領市場。 Theramex公司在歐洲和英國推出的「Bijuva/Bijuve」等知名新產品正在加速市場成長。
  • 荷爾蒙補充療法（GHRT）：由於生長激素缺乏症盛行率不斷上升，預計該療法將實現較高的複合年成長率。諾和諾德的諾德促生長素（Norditropin）和輝瑞/OPKO Health的索馬托洛根（Somatologun）等產品正在推動銷售成長。
  • 睾酮療法：隨著 Jatenzo（口服睾酮）和 Tlando 等藥物的核准，男性性腺功能低下症的治療選擇正在擴大，預計未來將穩步成長。
  • 甲狀腺荷爾蒙補充療法：甲狀腺機能低下症盛行率的增加以及 Thyquidity（VistaPharm，2020 年獲得 FDA核准）等新產品的核准，推動了該領域的成長。

透過申請：

  • 更年期：到 2026 年，這將成為最大的細分市場，佔市場佔有率的 56.8%，這主要得益於全球更年期女性人數的增加以及對雌激素和孕激素療法的需求不斷成長。
  • 甲狀腺機能低下症：由於甲狀腺疾病的盛行率不斷上升，這是第二大細分市場。
  • 生長激素缺乏症：這是一個全球性的主要問題，美國每年報告約有 6,000 例新的成人病例。
  • 男性性腺功能低下症：在美國，有 400 萬至 500 萬名男性患有這種疾病，而新的睪固酮療法的普及程度正在提高。

依管理途徑：

  • 口服給藥：由於其滲透率高、生產規模大，已成為全球主流的給藥方式。
  • 由於凝膠和貼劑的使用降低了口服治療的風險，經皮給藥方式得到了顯著發展。
  • 腸外給藥：預計這將導致最低的生長速度。

按分銷管道：

  • 醫院藥局：這是最廣泛採用的藥局類型，因為它們位於綜合醫院內，確保了藥品的可靠供應。
  • 普通藥局：在非處方荷爾蒙替代療法產品的支持下，它們做出了第二大貢獻。
  • 受人們對便利性和安全性的擔憂推動，網路藥局發展迅速，尤其是在疫情期間。

區域趨勢

  • 北美：預計到2025年將佔52.12%的市場佔有率，市場規模為93.5億美元，預計到2026年將達到99億美元。美國市場預計到2026年將達到84.5億美元。更年期疾病、男性性腺功能低下症和生長激素缺乏症的高發生率，以及高昂的醫療保健成本，是推動市場成長的主要因素。
  • 歐洲：預計到 2025 年市場規模將達到 30.2 億美元，到 2026 年將成長至 31.8 億美元。英國和德國是主要市場，女性荷爾蒙失調和老年人甲狀腺機能低下症的增加推動了需求成長。
  • 亞太地區：預計到 2025 年市場規模將達到 30.3 億美元，到 2026 年將達到 32.7 億美元。成長動力包括人們對停經後風險的認知不斷提高、未滿足的需求以及中國和日本核准的新治療方法。
  • 拉丁美洲和中東及非洲：預計到 2025 年，市場佔有率將相對較小（分別為 11.4 億美元和 14 億美元），並且由於認知度低和需求未得到滿足，預計成長緩慢。

市場趨勢和成長要素

  • 先進藥物傳輸系統（如經皮吸收貼片、凝膠和低劑量雌激素製​​劑）的引入，正在推動市場擴張。
  • 隨著人們對個人化醫療和精準荷爾蒙療法的關注度不斷提高，考慮到遺傳因素、生活方式和荷爾蒙水平的客製化治療方案正變得越來越可靠。
  • 全球更年期症狀和生長激素缺乏症的日益普遍，正在推動新產品的開發和研發。
  • 生物同源荷爾蒙療法和生物相容性化合物產品（如 Bijuva/Bijuve）等創新技術提高了安全性和有效性。

抑制因子

  • 血栓、膽固醇水平變化、心血管風險和前列腺問題等副作用可能會限制其使用。
  • 高昂的治療費用是一個障礙，尤其是對於沒有保險的患者而言。
  • 監管挑戰、FDA核准延遲以及產品召回（例如 Dr. Reddy 的孕酮膠囊、Perrigo 的 Evamist 噴霧劑）可能會阻礙市場成長。

成長率：2026年至2034年的複合年成長率為6.38%。

透過治療方法

  • 雌激素和聯合治療
  • 甲狀腺荷爾蒙補充療法
  • 生長激素荷爾蒙補充療法
  • 睪固酮荷爾蒙補充療法

適應

  • 停經
  • 甲狀腺機能低下症
  • 男性性腺功能低下症
  • 生長激素缺乏症

透過行政途徑

  • 口服
  • 經皮
  • 腸外

透過分銷管道

  • 醫院藥房
  • 零售藥局和藥房
  • 網路藥房

按地區

  • 北美（按治療方法、適應症、給藥途徑、分銷管道和國家/地區分類）
    • 美國
    • 加拿大
  • 歐洲（依治療領域、適應症、給藥途徑、通路和國家/次區域分類）
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家
  • 亞太地區（依治療方法、適應症、給藥途徑、通路和國家/次區域分類）
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 亞太其他地區
  • 拉丁美洲（依治療方法、適應症、給藥途徑、通路和國家/次區域分類）
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中東和非洲（按治療方法、適應症、給藥途徑、分銷管道和國家/次區域分類）
    • GCC
    • 南非
    • 其他中東和非洲地區

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 主要企業管道分析
  • 產業重大發展動態－併購與合作
  • 新產品發布：按主要企業分類
  • 新冠疫情的影響：全球荷爾蒙補充療法市場

第5章：全球荷爾蒙補充療法市場分析、洞察與預測（2021-2034年）

  • 市場分析、洞察與預測：按治療方法
    • 雌激素和聯合荷爾蒙補充療法
    • 甲狀腺荷爾蒙補充療法
    • 生長激素荷爾蒙補充療法
    • 睪固酮荷爾蒙補充療法
  • 市場分析、洞察與預測：按適應症分類。
    • 停經
    • 甲狀腺機能低下症
    • 男性性腺功能低下症
    • 生長激素缺乏症
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 經皮
    • 腸外
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院和藥房
    • 零售藥局和藥房
    • 網路藥房
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美荷爾蒙補充療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲荷爾蒙補充療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區荷爾蒙補充療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲荷爾蒙補充療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲荷爾蒙補充療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2026 年）
  • 公司簡介
    • Novo Nordisk A/S
    • Pfizer Inc.
    • AbbVie Inc.
    • Merck KGaA
    • Endo Pharmaceuticals Solutions Inc.
    • Allergan
    • Eli Lilly and Company
    • Mithra Pharmaceuticals
    • Amgen
Product Code: FBI102543

Growth Factors of hormone replacement therapy (HRT) Market

The global hormone replacement therapy (HRT) market is witnessing substantial growth, driven by the rising prevalence of menopausal disorders, growth hormone deficiencies, hypothyroidism, and male hypogonadism. According to Fortune Business Insights, the HRT market size was valued at USD 17.94 billion in 2025. The market is projected to grow to USD 19.04 billion in 2026 and further expand to USD 31.23 billion by 2034, reflecting a CAGR of 6.38% during the forecast period.

Market Dynamics

Hormone replacement therapies are critical for treating menopause-related symptoms in women, including hot flashes, sleep disorders, anxiety, and osteoporosis, as well as hormone-related deficiencies in men and children. For instance, growth hormone deficiency in adults and pediatric populations, hypothyroidism, and male hypogonadism are all driving the adoption of HRT globally. The growing awareness of modern therapies and increased acceptance of estrogen and combination therapy, as well as transdermal and oral formulations, are key factors supporting market expansion.

The market faced temporary setbacks during the COVID-19 pandemic, primarily due to shortages in supply and disruptions in healthcare facilities, which impacted diagnosis and treatment. However, resumption of healthcare services and continued demand for these therapies have restored growth to pre-pandemic levels.

Market Segmentation

By Therapy Type:

  • Estrogen and Combination Therapy: Dominates the market with a projected 51.04% share globally in 2026, driven by awareness of menopausal symptoms and availability of multiple formulations such as gels, patches, and oral tablets. Notable product launches, including Bijuva/Bijuve by Theramex in Europe and the UK, are propelling growth.
  • Growth Hormone Replacement Therapy (GHRT): Expected to witness strong CAGR due to rising prevalence of growth hormone deficiencies. Products like Norditropin (Novo Nordisk) and somatrogon (Pfizer/OPKO Health) are leading in revenue growth.
  • Testosterone Therapy: Steady growth expected with approvals like Jatenzo (oral testosterone) and Tlando enhancing male hypogonadism treatment options.
  • Thyroid Hormone Replacement Therapy: Growth is supported by increasing hypothyroidism prevalence and new product approvals, such as Thyquidity (VistaPharm, FDA-approved in 2020).

By Indication:

  • Menopause: Largest segment with 56.8% market share in 2026, driven by the growing global population of menopausal women and increasing demand for estrogen-progesterone therapy.
  • Hypothyroidism: Second-largest segment due to rising thyroid disorder prevalence.
  • Growth Hormone Deficiency: A significant concern worldwide, with approximately 6,000 new adult cases annually in the U.S.
  • Male Hypogonadism: Affecting 4-5 million men in the U.S., treatment adoption is increasing with new testosterone therapies.

By Route of Administration:

  • Oral: Dominates globally due to widespread adoption and mass production.
  • Transdermal: Growing significantly due to gel and patch formulations reducing risks associated with oral therapy.
  • Parenteral: Expected to grow at the lowest rate.

By Distribution Channel:

  • Hospital Pharmacies: Largest adoption due to the presence of pharmacies in multispecialty hospitals, ensuring therapy availability.
  • Retail Pharmacies: Second-largest contributor, supported by over-the-counter HRT products.
  • Online Pharmacies: Witnessing rapid growth, especially post-pandemic, driven by convenience and safety concerns.

Regional Insights

  • North America: Dominates the market with 52.12% share in 2025, valued at USD 9.35 billion, projected to reach USD 9.9 billion in 2026. U.S. market expected to reach USD 8.45 billion in 2026. Growth driven by high prevalence of menopause, male hypogonadism, growth hormone deficiency, and high healthcare expenditure.
  • Europe: Valued at USD 3.02 billion in 2025, projected to grow to USD 3.18 billion in 2026. The UK and Germany are key markets, with rising hormonal disorders in women and geriatric hypothyroidism driving demand.
  • Asia Pacific: Market size of USD 3.03 billion in 2025, expected to reach USD 3.27 billion in 2026. Growth fueled by increased awareness of post-menopausal hazards, unmet medical needs, and novel therapy approvals in China and Japan.
  • Latin America and Middle East & Africa: Smaller market share in 2025 (USD 1.14 billion and USD 1.4 billion, respectively), projected for moderate growth due to low awareness and unmet needs.

Market Trends and Growth Factors

  • Launch of advanced drug delivery systems, such as transdermal patches, gels, and low-dose estrogen formulations, is driving market expansion.
  • Increasing focus on personalized medicine and precision hormone therapy ensures tailored treatments considering genetics, lifestyle, and hormone levels.
  • Rising prevalence of menopausal symptoms and growth hormone deficiency globally is encouraging new product development and R&D.
  • Innovations like bioidentical hormone therapies and body-identical combination products, such as Bijuva/Bijuve, enhance safety and efficacy.

Restraining Factors

  • Adverse effects, including blood clots, cholesterol changes, cardiovascular risks, and prostate issues, may limit adoption.
  • High therapy costs, particularly for uninsured patients, pose a barrier.
  • Regulatory challenges, delayed FDA approvals, and product recalls (e.g., Dr. Reddy's progesterone capsules, Perrigo Evamist spray) may impede growth.

Competitive Landscape

Key players in the global HRT market include:

  • Novo Nordisk A/S (Denmark) - Leading with Norditropin and Sogroya for growth hormone deficiencies.
  • Pfizer Inc. (U.S.) - Known for Genotropin and somatrogon development.
  • AbbVie, Merck KGaA, Endo International, Allergan, Eli Lilly, Mithra Pharmaceuticals, Amgen - Active in product launches, approvals, and R&D.

Notable Developments:

  • June 2023 - Pfizer reintroduced DUAVEE with enhanced packaging.
  • June 2022 - Launch of Tlando (oral testosterone) in the U.S.
  • May 2021 - Myovant Sciences received FDA approval for Myfembree.
  • April 2021 - BIJUVE approved in U.K. and Belgium.
  • October 2020 - Positive Phase 3 results for somatrogon in pediatric growth hormone deficiency.

Conclusion

The global hormone replacement therapy market is on a strong growth trajectory, expanding from USD 17.94 billion in 2025 to USD 31.23 billion by 2034, driven by increasing hormonal disorders, aging populations, and technological innovations in drug delivery. North America continues to lead the market, while Asia Pacific presents emerging opportunities. The combination of advanced therapies, personalized medicine, and strong R&D initiatives by key players like Novo Nordisk and Pfizer is expected to sustain long-term growth, despite challenges such as side effects, high costs, and regulatory hurdles.

Growth Rate CAGR of 6.38% from 2026-2034

By Therapy Type

  • Estrogen and Combinations Replacement Therapy
  • Thyroid Hormone Replacement Therapy
  • Growth Hormone Replacement Therapy
  • Testosterone Hormone Replacement Therapy

By Indication

  • Menopause
  • Hypothyroidism
  • Male Hypogonadism
  • Growth Hormone Deficiency

By Route of Administration

  • Oral
  • Transdermal
  • Parenteral

By Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Geography

  • North America (By Therapy Type, By Indication, By Route of Administration, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Therapy Type, By Indication, By Route of Administration, By Distribution Channel, and By Country/Sub region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Therapy Type, By Indication, By Route of Administration, By Distribution Channel, and By Country/Sub region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Therapy Type, By Indication, By Route of Administration, By Distribution Channel, and By Country/Sub region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Therapy Type, By Indication, By Route of Administration, By Distribution Channel, and By Country/Sub region)
    • GCC
    • South Africa
    • Rest of the Middle East and Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Pipeline Analysis, By Key Players
  • 4.2. Key Industry Developments - Mergers, Acquisitions, and Collaborations
  • 4.3. New Product Launches, By Key Players
  • 4.4. Impact of COVID-19 on the Global Hormone Replacement Therapy Market

5. Global Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 5.1.1. Estrogen and Combinations Replacement Therapy
    • 5.1.2. Thyroid Hormone Replacement Therapy
    • 5.1.3. Growth Hormone Replacement Therapy
    • 5.1.4. Testosterone Hormone Replacement Therapy
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Menopause
    • 5.2.2. Hypothyroidism
    • 5.2.3. Male hypogonadism
    • 5.2.4. Growth hormone deficiency
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Transdermal
    • 5.3.3. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospitals Pharmacies
    • 5.4.2. Retail Pharmacies & Drug Stores
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 6.1.1. Estrogen and Combinations Replacement Therapy
    • 6.1.2. Thyroid Hormone Replacement Therapy
    • 6.1.3. Growth Hormone Replacement Therapy
    • 6.1.4. Testosterone Hormone Replacement Therapy
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Menopause
    • 6.2.2. Hypothyroidism
    • 6.2.3. Male hypogonadism
    • 6.2.4. Growth hormone deficiency
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Transdermal
    • 6.3.3. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospitals Pharmacies
    • 6.4.2. Retail Pharmacies & Drug Stores
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 7.1.1. Estrogen and Combinations Replacement Therapy
    • 7.1.2. Thyroid Hormone Replacement Therapy
    • 7.1.3. Growth Hormone Replacement Therapy
    • 7.1.4. Testosterone Hormone Replacement Therapy
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Menopause
    • 7.2.2. Hypothyroidism
    • 7.2.3. Male hypogonadism
    • 7.2.4. Growth hormone deficiency
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Transdermal
    • 7.3.3. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospitals Pharmacies
    • 7.4.2. Retail Pharmacies & Drug Stores
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 8.1.1. Estrogen and Combinations Replacement Therapy
    • 8.1.2. Thyroid Hormone Replacement Therapy
    • 8.1.3. Growth Hormone Replacement Therapy
    • 8.1.4. Testosterone Hormone Replacement Therapy
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Menopause
    • 8.2.2. Hypothyroidism
    • 8.2.3. Male hypogonadism
    • 8.2.4. Growth hormone deficiency
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Transdermal
    • 8.3.3. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospitals Pharmacies
    • 8.4.2. Retail Pharmacies & Drug Stores
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 9.1.1. Estrogen and Combinations Replacement Therapy
    • 9.1.2. Thyroid Hormone Replacement Therapy
    • 9.1.3. Growth Hormone Replacement Therapy
    • 9.1.4. Testosterone Hormone Replacement Therapy
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Menopause
    • 9.2.2. Hypothyroidism
    • 9.2.3. Male hypogonadism
    • 9.2.4. Growth hormone deficiency
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Transdermal
    • 9.3.3. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospitals Pharmacies
    • 9.4.2. Retail Pharmacies & Drug Stores
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 10.1.1. Estrogen and Combinations Replacement Therapy
    • 10.1.2. Thyroid Hormone Replacement Therapy
    • 10.1.3. Growth Hormone Replacement Therapy
    • 10.1.4. Testosterone Hormone Replacement Therapy
  • 10.2. Market Analysis, Insights and Forecast - By Indication
    • 10.2.1. Menopause
    • 10.2.2. Hypothyroidism
    • 10.2.3. Male hypogonadism
    • 10.2.4. Growth hormone deficiency
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Transdermal
    • 10.3.3. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospitals Pharmacies
    • 10.4.2. Retail Pharmacies & Drug Stores
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2026)
  • 11.2. Company Profiles
    • 11.2.1. Novo Nordisk A/S
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. AbbVie Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Merck KGaA
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Endo Pharmaceuticals Solutions Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Allergan
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Eli Lilly and Company
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Mithra Pharmaceuticals
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Amgen
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Therapy Type, 2021-2034
  • Table 2: Global Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 3: Global Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Therapy Type, 2021-2034
  • Table 7: North America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 8: North America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Therapy Type, 2021-2034
  • Table 12: Europe Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 13: Europe Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Europe Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Asia Pacific Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Therapy Type, 2021-2034
  • Table 18: Asia Pacific Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 19: Asia Pacific Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 20: Asia Pacific Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 21: Asia Pacific Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 22: Latin America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Therapy Type, 2021-2034
  • Table 23: Latin America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 24: Latin America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 25: Latin America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 26: Latin America Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 27: Middle East & Africa Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Therapy Type, 2021-2034
  • Table 28: Middle East & Africa Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 29: Middle East & Africa Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 30: Middle East & Africa Hormone Replacement Therapy Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 31: Middle East & Africa Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 32: GCC Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Therapy Type, 2021-2034
  • Table 33: South Africa Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Therapy Type, 2021-2034
  • Table 34: Rest of Middle East & Africa Hormone Replacement Therapy Market Revenue (USD billion) Forecast, By Therapy Type, 2021-2034

List of Figures

  • Figure 1: Global Hormone Replacement Therapy Market Revenue Breakdown (USD billion, %) by Region, 2026 & 2034
  • Figure 2: Global Hormone Replacement Therapy Market Value Share (%), by Therapy Type, 2026 & 2034
  • Figure 3: Global Hormone Replacement Therapy Market Value Share (%), by Indication, 2026 & 2034
  • Figure 4: Global Hormone Replacement Therapy Market Value Share (%), by Route of Administration, 2026 & 2034
  • Figure 5: Global Hormone Replacement Therapy Market Value Share (%), by Distribution Channel, 2026 & 2034
  • Figure 6: Global Hormone Replacement Therapy Market Value (USD billion), by Region, 2026 & 2034
  • Figure 7: North America Hormone Replacement Therapy Market Value (USD billion), by Therapy Type, 2026 & 2034
  • Figure 8: North America Hormone Replacement Therapy Market Value Share (%), by Therapy Type, 2026
  • Figure 9: North America Hormone Replacement Therapy Market Value (USD billion), by Indication, 2026 & 2034
  • Figure 10: North America Hormone Replacement Therapy Market Value Share (%), by Indication, 2026
  • Figure 11: North America Hormone Replacement Therapy Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 12: North America Hormone Replacement Therapy Market Value Share (%), by Route of Administration, 2026
  • Figure 13: North America Hormone Replacement Therapy Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 14: North America Hormone Replacement Therapy Market Value Share (%), by Distribution Channel, 2026
  • Figure 15: North America Hormone Replacement Therapy Market Value (USD billion), By Country, 2026 & 2034
  • Figure 16: North America Hormone Replacement Therapy Market Value Share (%), By Country, 2026
  • Figure 17: Europe Hormone Replacement Therapy Market Value (USD billion), by Therapy Type, 2026 & 2034
  • Figure 18: Europe Hormone Replacement Therapy Market Value Share (%), by Therapy Type, 2026
  • Figure 19: Europe Hormone Replacement Therapy Market Value (USD billion), by Indication, 2026 & 2034
  • Figure 20: Europe Hormone Replacement Therapy Market Value Share (%), by Indication, 2026
  • Figure 21: Europe Hormone Replacement Therapy Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 22: Europe Hormone Replacement Therapy Market Value Share (%), by Route of Administration, 2026
  • Figure 23: Europe Hormone Replacement Therapy Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 24: Europe Hormone Replacement Therapy Market Value Share (%), by Distribution Channel, 2026
  • Figure 25: Europe Hormone Replacement Therapy Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 26: Europe Hormone Replacement Therapy Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 27: Asia Pacific Hormone Replacement Therapy Market Value (USD billion), by Therapy Type, 2026 & 2034
  • Figure 28: Asia Pacific Hormone Replacement Therapy Market Value Share (%), by Therapy Type, 2026
  • Figure 29: Asia Pacific Hormone Replacement Therapy Market Value (USD billion), by Indication, 2026 & 2034
  • Figure 30: Asia Pacific Hormone Replacement Therapy Market Value Share (%), by Indication, 2026
  • Figure 31: Asia Pacific Hormone Replacement Therapy Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 32: Asia Pacific Hormone Replacement Therapy Market Value Share (%), by Route of Administration, 2026
  • Figure 33: Asia Pacific Hormone Replacement Therapy Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 34: Asia Pacific Hormone Replacement Therapy Market Value Share (%), by Distribution Channel, 2026
  • Figure 35: Asia Pacific Hormone Replacement Therapy Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 36: Asia Pacific Hormone Replacement Therapy Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 37: Latin America Hormone Replacement Therapy Market Value (USD billion), by Therapy Type, 2026 & 2034
  • Figure 38: Latin America Hormone Replacement Therapy Market Value Share (%), by Therapy Type, 2026
  • Figure 39: Latin America Hormone Replacement Therapy Market Value (USD billion), by Indication, 2026 & 2034
  • Figure 40: Latin America Hormone Replacement Therapy Market Value Share (%), by Indication, 2026
  • Figure 41: Latin America Hormone Replacement Therapy Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 42: Latin America Hormone Replacement Therapy Market Value Share (%), by Route of Administration, 2026
  • Figure 43: Latin America Hormone Replacement Therapy Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 44: Latin America Hormone Replacement Therapy Market Value Share (%), by Distribution Channel, 2026
  • Figure 45: Latin America Hormone Replacement Therapy Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 46: Latin America Hormone Replacement Therapy Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 47: Middle East & Africa Hormone Replacement Therapy Market Value (USD billion), by Therapy Type, 2026 & 2034
  • Figure 48: Middle East & Africa Hormone Replacement Therapy Market Value Share (%), by Therapy Type, 2026
  • Figure 49: Middle East & Africa Hormone Replacement Therapy Market Value (USD billion), by Indication, 2026 & 2034
  • Figure 50: Middle East & Africa Hormone Replacement Therapy Market Value Share (%), by Indication, 2026
  • Figure 51: Middle East & Africa Hormone Replacement Therapy Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 52: Middle East & Africa Hormone Replacement Therapy Market Value Share (%), by Route of Administration, 2026
  • Figure 53: Middle East & Africa Hormone Replacement Therapy Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 54: Middle East & Africa Hormone Replacement Therapy Market Value Share (%), by Distribution Channel, 2026
  • Figure 55: Middle East & Africa Hormone Replacement Therapy Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 56: Middle East & Africa Hormone Replacement Therapy Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 57: Global Hormone Replacement Therapy Market Share (%), By Company, 2026